Skip to main content
OpenTrials
Completed

NCT Number: NCT07374484

Longitudinal Dynamics of AT1R Antibodies in Kidney Transplant Recipients

This study aims to investigate the dynamics of Angiotensin II Type 1 Receptor Antibodies (AT1R-Ab) before and after kidney transplantation. The purpose is to understand how changes in AT1R-Ab levels may impact post-transplant kidney function and graft survival. Participants will include kidney transplant recipients, and their AT1R-Ab levels will be monitored over a one-year period. This research may help develop better predictive models for transplant outcomes, improving clinical decision-making for transplant physicians.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Transplantation Angiotensin II Type 1 Receptor Antibody Graft Survival

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Hospital

Seoul, 03080, South Korea

About this study

The study will be conducted as a prospective cohort study involving kidney transplant recipients. The participants will undergo monitoring of their AT1R-Ab levels at multiple time points before and after the transplantation, including 2 weeks, 3 months, and 1 year post-transplant. Data collected will include clinical information such as kidney function tests, graft survival rates, and post-transplant complications. The study will aim to correlate AT1R-Ab dynamics with clinical outcomes such as delayed graft function (DGF), graft loss, and creatinine levels.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Eligible patients were those who had serum samples collected at pre-transplant and at 2 weeks, 3 months, and 1-year post-transplant, with a minimum follow-up of 1 year

Exclusion criteria

Exclusion criteria

were simultaneous multi-organ transplantation and age younger than 18 years.

Treatment and study plan

Primary outcomes

  1. Biopsy-Proven Acute Rejection (BPAR) within 3 years post-transplant

    Time frame: Up to 3 years post-transplant

    This study evaluates biopsy-proven acute rejection (BPAR) as the primary outcome, using protocol biopsies at 2 weeks and 1 year post-transplant.

Secondary outcomes

  1. Renal Function: Serum Creatinine and eGFR at 2 weeks, 3 months, and 1 year post-transplant

    Time frame: At 2 weeks, 3 months, and 1 year post-transplant

    Secondary outcomes will include renal function, assessed by serum creatinine and eGFR at 2 weeks, 3 months, and 1 year post-transplant. The relationship between AT1R-Ab levels and renal function will be analyzed.

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • Ministry of Health, Republic of Korea

Registry information

Official study title

Longitudinal Dynamics of Angiotensin II Type 1 Receptor Antibodies Around Kidney Transplantation and Their Impact on Clinical Outcomes

Acronym: AT1R

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 28, 2026
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.